ICR welcomes recommendation of talazoparib for advanced breast cancer 19 Jan 2024 The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer. Find out more Show/Hide
Existing cancer drugs have potential to benefit thousands more patients 31 Jul 2023 Existing targeted cancer drugs could help even more patients, including some with the most common type of breast cancer, scientists have discovered. Find out more Show/Hide